Fibrin degradation product is the substances which stay in the bloodstream after the body dissolves a blood clot. The clot-busting i.e. fibrinolytic system regulates and manages the clot-dissolving in the body. Fibrin degradation product assay identifies the occurrence of fibrin degradation products of circulating fragments such as non-cross linked i.e. soluble fibrin and fibrinogen which is produced due to the plasmin action.
Similarly, plasmin produces an initial cleavage product known as fragment X by acting on the two substrates. After that plasmin acts on fragment X and then cleave it into a temporary fragment Y, and D. Additionally, fragment D, Fragment E and the terminal fibrinogen degradation products are then produced by fragment Y cleavage.
Therefore, from one molecule of soluble fibrin or fibrinogen, fragments D, one terminal fragment E, and 2 terminal fibrin degradation product are produced.
Based on several studies by the Centers for Disease Control and Prevention, estimates that the venous thromboembolism or blood clot disorder affects more than 9 million people in the U.S. each year. Approximately 60,000 to 1 million Americans die as a result of venous thromboembolism or blood clot disorder.
This factor has increased the authority and healthcare system to pay more attention towards the burden of blood-related disorders which in turn increases the market growth for fibrin degradation product assay market. However, the fibrin degradation product assay is used with the other blood coagulation tests to distinguish bleeding disorders more precisely.
Without the assessment of results and clinical signs of other coagulation tests, the fibrin degradation product assay based test results should not be interpreted alone. This factor may influence the result at first and are likely to hamper the fibrin degradation product assays market growth.
Rising prevalence of blood-related disorders such as blood clots, hemophilia, leukemia, lymphoma, and myeloma are the major factor to increase the market growth for the fibrin degradation product assays market. Growing prevalence of these diseases increase the number of fibrin degradation product assays based testing and is expected to contribute to the growth of fibrin degradation product assays market.
The large percentage of the population especially from the developing countries such as India, China, Brazil, and Mexico lack awareness regarding the management of blood-related disorders. This factor is expected to greatly impact the growth of fibrin degradation product assays market.
Moreover, lack of awareness regarding the available test and unavailability of proper facilities and skilled professionals may limit the growth of the fibrin degradation product assays market in the forecast years.
The Asia-Pacific fibrin degradation product assays market is expected to grow at a moderate growth rate, however, is likely to show a large patient pool in the forecast years. The anemic condition is very much prominent in the regions like Southeast and Asian regions. These factors are likely to hamper the market growth of fibrin degradation product assays in these regions.
The North America fibrin degradation product assays market is expected to show high growth of the fibrin degradation product assays market because the compliance rate of blood testing in the region is high coupled with advance facilities. Some major countries like U.S., U.K., Germany, Australia has compulsory the blood test for various disease per year.
The Oceania fibrin degradation product assays market is expected to be prominent for the fibrin degradation product assays market due to the high incidence rate of melanoma cancer, high adoption rate, increasing healthcare spending and advance healthcare systems.
Some of the key players present in global fibrin degradation product assays market includes Sekisui Diagnostics (Sekisui Chemical), Randox Laboratories, Beckman Coulter Inc. (Danaher Corporation), Kamiya Biomedical Company, ADALTIS S.r.l., SDIX, LLC, Lab Mark A.s., Abbott Laboratories, IBL International (Tecan Group Ltd.), Analytik Jena AG, and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global fibrin degradation product assays market is segmented by reagent type, sample type, end user, and regions:
Fibrin Degradation Product Assays Segmentation by Reagent Type
Fibrin Degradation Product Assays Segmentation by Sample Type
Fibrin Degradation Product Assays Segmentation by End User
Explore Similar Insights
Fibrin Degradation Product (FnDP) Assays Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
